Quote · Huberman Lab
Accelerate Learning & Increase Cognitive Capacity | Dr. Tommy Wood
Where this was said
Cognitive Decline, Dementia, Alzheimer's Disease, Modifiable Risk Factors
At 2:05:10 · chapter starts 2:03:37
Wood frames dementia not as a sudden disease but as the end stage of a long trajectory of decline that in principle could be interrupted much earlier — the way diabetes prevention should start well before diagnosis. Alzheimer's accounts for 60–80% of cases and overlaps substantially with vascular dementia (most Alzheimer's patients also have cerebrovascular pathology). The rare monogenic forms of Alzheimer's — presenilin 1, presenilin 2, APP mutations — account for less than 5% and possibly as little as 1% of cases. Late-onset Alzheimer's has a genetic component (APOE being the dominant risk gene), but lifestyle and environment are the primary drivers. The Lancet Commission's 14 modifiable risk factors include: early life education, hypertension, diabetes, hearing loss, vision loss, brain trauma, high LDL, physical inactivity, social isolation, depression, smoking, excessive alcohol, air pollution, and obesity. Together they account for ~45% of cases; sleep deprivation and nutrient deficiencies were notably omitted by the Commission despite evidence Wood argues is comparably strong. Some analyses suggest 70% of dementia may be preventable if socioeconomic and environmental factors are included.
The Lancet Commission on Dementia Prevention identified 14 modifiable risk factors that together account for approximately 45% of dementia cases — and some analyses suggest the figure could be as high as 70%.
Data on sleep and dementia risk consistently show that the threshold for elevated risk is approximately 6 hours of nightly sleep — those consistently below this level face significantly increased dementia risk.
Natural experiments in Wales, Australia, and Canada consistently showed that people who received the shingles vaccine had a significantly lower risk of dementia compared to those who did not.
Natural experiments in Wales, Australia, and Canada — where eligibility switched based on birth date — consistently showed lower dementia rates among shingles vaccine recipients. The newer Shingrix vaccine appears more protective than the older Zostavax. The leading hypothesis is an immunomodulatory effect that may also suppress other neurotropic herpesviruses.
